Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Crowley John F
   2. Issuer Name and Ticker or Trading Symbol
AMICUS THERAPEUTICS INC [FOLD] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chairman & CEO
(Last)
(First)
(Middle)
C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE		 3. Date of Earliest Transaction (Month/Day/Year)
10/12/2017
(Street)

CRANBURY, NJ 08512		 4. If Amendment, Date Original Filed(Month/Day/Year)
10/17/2017		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/12/2017   M(1)   380,000 A $ 14.2495 (2) 708,001 D  
Common Stock 10/12/2017   S(1)   380,000 D $ 14.2495 (3) 328,001 D  
Common Stock 10/13/2017   M(1)   22,160 A $ 14.7503 (4) 350,161 D  
Common Stock 10/13/2017   S(1)   22,160 D $ 14.7503 (5) 328,001 D  
Common Stock 10/16/2017   M(1)   47,135 A $ 14.75 375,136 D  
Common Stock 10/16/2017   S(1)   47,135 D $ 14.75 328,001 D  
Common Stock               64,895 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (right to buy) $ 6.45 10/12/2017   M(1)     5,783 02/15/2016 02/15/2022 Common Stock 5,783 $ 0 131,024 D  
Stock Options (right to buy) $ 4.38 10/12/2017   M(1)     13,622 06/04/2016 06/04/2022 Common Stock 13,622 $ 0 136,378 D  
Stock Options (right to buy) $ 3.53 10/12/2017   M(1)     3,462 01/28/2017 01/28/2023 Common Stock 3,462 $ 0 161,538 D  
Stock Options (right to buy) $ 2.52 10/12/2017   M(1)     165,000 06/18/2017 06/18/2023 Common Stock 165,000 $ 0 0 D  
Stock Options (right to buy) $ 3.19 10/12/2017   M(1)     192,133 01/03/2015 01/03/2024 Common Stock 192,133 $ 0 20,972 D  
Stock Options (right to buy) $ 3.53 10/13/2017   M(1)     22,160 01/28/2017 01/28/2023 Common Stock 22,160 $ 0 139,378 D  
Stock Options (right to buy) $ 3.53 10/16/2017   M(1)     47,135 01/28/2017 01/28/2023 Common Stock 47,135 $ 0 92,243 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Crowley John F
C/O AMICUS THERAPEUTICS, INC.
1 CEDAR BROOK DRIVE
CRANBURY, NJ 08512		   X     Chairman & CEO  

Signatures

 /s/ John F. Crowley   10/20/2017
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017.
(2) This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.09 to $14.44. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
(3) This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.09 to $14.44. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
(4) This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.79. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
(5) This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.79. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
 
Remarks:
This Form 4 amendment corrects the reporting person's Remarks from the originally filed Form 4.  The Remarks should read as follows:  Shares were sold to fund the "Megan K. Crowley 2016 Special Needs Trust", a trust for the benefit of Mr. Crowley's child, with the balance of the proceeds used for general estate planning purposes.  The total shares sold represented less than 14% of Mr. Crowley's holdings of securities of the company and after these transactions, Mr. Crowley's percentage of shares beneficially owned is 1% of the company's outstanding shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.